Efficacy of Bravecto® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) in the prevention of feline Aelurostrongylus abstrusus infection evaluated in a multi-diagnostic approach

Table 1 Parasitological parameters of the 27 study animals of the investigational veterinary product (IVP)-treated groups (Bravecto^® Plus spot-on solution, minimum recommended dose of 40 mg fluralaner and 2.0 mg moxidectin/kg body weight; G1, G2, G3) and the control group (0.9% saline; G4)

Group	Animal ID	First day of L1 excretion (dpi/SD)	Max. L1 count/day in 5 g faeces	GM of max. L1 count/day	Efficacy [%]	p-value
G1 (IVP treatment 12 weeks prior to infection)	1270	38/122^a	2	1.63	99.98	<0.0001*
	2827	n.a.	0
	3098	42/126^a	1
	3132	38/122^b	1
	3136	n.a.	0
	3185	38/122^a	8
	3199	41/125^a	7
G2 (IVP treatment 8 weeks prior to infection)	0157	n.a.	0	1.37	99.98	<0.0001*
	1016	46/130^a	1
	1149	41/125^a	29
	1781	n.a.	0
	2690	n.a.	0
	2955	39/123^b	6
	3283	n.a.	0
G3 (IVP treatment 4 weeks prior to infection)	0362	43/127^a	2	0.79	99.99	<0.0001*
	2355	n.a.	0
	2788	n.a.	0
	3029	n.a.	0
	3046	43/127^a	4
	3150	n.a.	0
	3207	45/129^a	3
G4 (no IVP treatment, control)	0262	37/121	4170	7380.89	–	–
	1771	35/119	10140
	2510	33/117	22104
	2659	36/120	6171
	2681	36/120	2370
	2816	34/118	11825

Preventive drug efficacy with comparison of log-transformed individual maximum first-stage larvae (L1) counts of the IVP treatment groups versus the control group by two-sided two-sample t-test. Note that one animal of the control group was excluded prior to infection on SD 79 due to an anaesthesia incident during CT examination
n.a.: No larvae excretion during the entire study
* Statistically significant by two-sided two-sample t-test
^a Larval excretion on single occasions
^b Larval excretion on two consecutive days

ISSN: 1756-3305